Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX5AP | P20292 | 1/20 | 0.47 |
| ▸ | FEN1 | P39748 | 1/20 | 0.47 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.47 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.47 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.46 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.46 |
| ▸ | UCHL1 | P09936 | 1/20 | 0.44 |
| ▸ | F2RL3 | Q96RI0 | 4/20 | 0.43 |
| ▸ | FPR3 | P25089 | 1/20 | 0.43 |
| ▸ | FPR2 | P25090 | 1/20 | 0.43 |
| ▸ | GPR119 | Q8TDV5 | 5/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23579441 | 1.00 | ALOX5AP (0.47) | ALOX5APFEN1CHRNB2CHRNA4CHRNB4 | |
| SCHEMBL30743365 | 1.00 | ALOX5AP (0.47) | ALOX5APFEN1CHRNB2CHRNA4CHRNB4 | |
| SCHEMBL26783267 | 1.00 | ALOX5AP (0.47) | ALOX5APFEN1CHRNB2CHRNA4CHRNB4 | |
| SCHEMBL29529911 | 0.94 | GPR119 (0.43) | ALOX5APFEN1CHRNB2CHRNA4CHRNB4 | |
| SCHEMBL24399166 | 0.94 | GPR119 (0.43) | ALOX5APFEN1CHRNB2CHRNA4CHRNB4 | |
| SCHEMBL23605880 | 0.94 | GPR119 (0.43) | ALOX5APFEN1CHRNB2CHRNA4CHRNB4 | |
| SCHEMBL29508261 | 0.94 | GPR119 (0.43) | ALOX5APFEN1CHRNB2CHRNA4CHRNB4 | |
| SCHEMBL22602644 | 0.86 | ALOX5AP (0.48) | ALOX5APFEN1CHRNB2CHRNA4CHRNB4 | |
| SCHEMBL22602678 | 0.86 | ALOX5AP (0.48) | ALOX5APFEN1CHRNB2CHRNA4CHRNB4 | |
| SCHEMBL29102386 | 0.86 | ALOX5AP (0.48) | ALOX5APFEN1CHRNB2CHRNA4CHRNB4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4565584-A1 | 1H-PYRROLO[3,2-B]PYRIDINE DERIVATIVES AS IRREVERSIBLE INHIBITORS OF MUTANT EGFR FOR THE TREATMENT OF CANCER | Bayer Aktiengesellschaft (DE) | 2025-06-11 | — | — | EP | disclosed |
| WO-2024028316-A1 | 1H-PYRROLO[3,2-B]PYRIDINE DERIVATIVES AS IRREVERSIBLE INHIBITORS OF MUTANT EGFR FOR THE TREATMENT OF CANCER | BAYER AKTIENGESELLSCHAFT (DE) | 2024-02-08 | — | — | WO | disclosed |
| EP-4217070-A1 | PYRROLO[3,2-C]PYRIDIN-4-ONE DERIVATIVES USEFUL IN THE TREATMENT OF CANCER | Scorpion Therapeutics, Inc. (US) | 2023-08-02 | — | — | EP | disclosed |
| WO-2022066734-A1 | PYRROLO[3,2-C]PYRIDIN-4-ONE DERIVATIVES USEFUL IN THE TREATMENT OF CANCER | SCORPION THERAPEUTICS, INC. (US) | 2022-03-31 | — | — | WO | disclosed |